We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

73 hedge funds and large institutions have $299M invested in Cogent Biosciences in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

6% more funds holding

Funds holding: 69 → 73 (+4)

5% more capital invested

Capital invested by funds: $284M → $299M (+$15.4M)

1.06% more ownership

Funds ownership: 94.74% → 95.8% (+1.1%)

5% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 19

Holders
73
Holders Change
+4
Holders Change %
+5.8%
% of All Funds
1.28%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
14
Increased
18
Reduced
19
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
VC
Vivo Capital
California
+$10.9M
2
CC
Commodore Capital
New York
+$4.18M
3
SCM
Silverarc Capital Management
Massachusetts
+$3.68M
4
MWNA
Marshall Wace North America
New York
+$2.51M
5
PCH
Polar Capital Holdings
United Kingdom
+$1.75M

Top Sellers

1
HA
HHLR Advisors
Cayman Islands
-$8.11M
2
Invesco
Invesco
Georgia
-$5.5M
3
TCM
Tekla Capital Management
Massachusetts
-$4.36M
4
LGM
Logos Global Management
California
-$3.8M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$26.8M – – –
BlackRock
2
BlackRock
New York
$23M +$420K +54,847 +2%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$21M +$427K +55,760 +2%
CS
4
Candriam SCA
Luxembourg
$16.2M +$127K +16,529 +0.9%
CC
5
Commodore Capital
New York
$16.1M +$4.18M +544,929 +40%
ABG
6
Ally Bridge Group
New York
$13.6M – – –
DM
7
Deerfield Management
New York
$13.5M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$13.4M -$74.1K -9,673 -0.6%
FFM
9
Fairmount Funds Management
Pennsylvania
$13.1M – – –
BI
10
BVF Inc
California
$12.9M – – –
GTC
11
Ghost Tree Capital
New York
$12.6M -$766K -100,000 -6%
VC
12
Vivo Capital
California
$11.9M +$10.9M +1,420,941 New
VA
13
VR Adviser
New York
$9.16M – – –
RCM
14
RA Capital Management
Massachusetts
$8.63M – – –
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$8.46M -$3.66M -477,792 -32%
PIM
16
Platinum Investment Management
Australia
$8.26M +$1.2M +156,179 +19%
LGM
17
Logos Global Management
California
$7.78M -$3.8M -495,500 -35%
AVAI
18
Atlas Venture Associates IX
Massachusetts
$7.71M – – –
SCM
19
Silverarc Capital Management
Massachusetts
$5.7M +$3.68M +479,655 +242%
FCM
20
Farallon Capital Management
California
$5.05M – – –
Axa
21
Axa
France
$4.96M +$166K +21,659 +4%
State Street
22
State Street
Massachusetts
$4.9M +$584K +76,158 +15%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$4.86M +$29.8K +3,895 +0.7%
NLVP
24
New Leaf Venture Partners
New York
$4.22M – – –
Northern Trust
25
Northern Trust
Illinois
$2.78M -$88.5K -11,544 -3%
1
2 3 4

COGT Hedge Fund Activity: Q3 2021 in Review

73 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2021, worth a combined $299M — up 5.4% from $284M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new COGT positions and 9 closed out — a net gain of 5 holders — while 18 added to existing stakes and 19 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $10.9M. The largest seller was HHLR Advisors, exiting entirely with an estimated $8.11M sold.

  • 73 institutional investors held Cogent Biosciences (COGT) as of Q3 2021, up from 69 in Q2 2021.
  • Funds reported $299M of Cogent Biosciences stock for Q3 2021, up 5.4% quarter-over-quarter.
  • 14 funds opened new Cogent Biosciences positions in Q3 2021 and 9 closed out, a net change of +5 holders.
  • The largest Cogent Biosciences buyer in Q3 2021 was Vivo Capital, an estimated $10.9M added.
  • The largest Cogent Biosciences seller in Q3 2021 was HHLR Advisors, an estimated $8.11M sold.

Based on aggregated 13F filings for Q3 2021.